Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NANT Hepatocellular Carcinoma Vaccine
- Development stage
- Discontinued
- Lead developer
- ImmunityBio
- Modality
- Small Molecules, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Oral, Subcutaneous
01
Overview
**NANT Hepatocellular Carcinoma Vaccine** is an investigational, multi-agent immuno-oncology regimen studied in QUILT-3.072 for advanced, unresectable, untransplantable hepatocellular carcinoma. The regimen combined antigen-directed adenoviral vaccines targeting carcinoembryonic antigen, mucin-1, and brachyury; yeast-based vaccines targeting RAS, carcinoembryonic antigen, and brachyury; haNK allogeneic natural killer-cell therapy; the IL-15 superagonist N-803; and selected metronomic chemotherapy, antibodies, targeted therapy, and stereotactic body radiation therapy. Its intended mechanism was to prime antigen-specific T-cell immunity, augment innate NK-cell cytotoxicity, and improve tumor-antigen exposure and immune recognition. The Phase 1b/2 study was withdrawn. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03563170))
- Other names
- NANT HCC VaccineQUILT-3.072QUILT3.072QUILT 3.072
02
Targets
DNAIL15RA (Interleukin-15 receptor subunit alpha)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on NANT Hepatocellular Carcinoma Vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NANT Hepatocellular Carcinoma Vaccine.